November 2019 Vol 12, No 7

David B. Nash, MD, MBA

Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia

David Campbell, PharmD, MS; Marlo Blazer, PharmD, BCOP; Lisa Bloudek, PharmD, MS; John Brokars, MS; Dinara Makenbaeva, MD, MBA

Stakeholder Perspective

The Challenges in Budgeting Potential Savings with the Launch of Generic Drugs

James T. Kenney, RPh, MBA

Industry Trends

Key Trends in Healthcare for 2020 and Beyond

F. Randy Vogenberg, PhD; John Santilli, MBA

Business, Original Research

The Economic Implications of Hyperkalemia in a Medicaid Managed Care Population

Nihar R. Desai, MD, MPH; Pamala Reed, DrPH, MPH; Paula J. Alvarez, RPh, MBA, MPH; Jeanene Fogli, PhD, RD; Steven D. Woods, PharmD; Mary Kay Owens, RPh, CPh

Stakeholder Perspective

The Impact of Quality Care on a Medicaid Population with Hyperkalemia

Byron C. Scott, MD, MBA

FDA Approvals

FDA Oncology Update

Results 1 - 5 of 5